Business Context and Reporting Period
Company: Humana Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2006
Business Overview: Humana is a major health benefits company operating two primary segments: Government (Medicare, TRICARE, Medicaid) and Commercial (employer groups, individuals). The reporting period reflects significant expansion in Medicare Advantage and Medicare Part D (PDP) membership, alongside the acquisition of CHA Health in Kentucky.
Key Financial Metrics
| Metric (Nine Months Ended Sep 30, 2006) | Value (in thousands) |
|---|---|
| Total Revenues | $15,761,318 |
| Net Income | $332,402 |
| Diluted Earnings Per Share | $1.98 |
| Operating Cash Flow | $1,151,811 |
| Cash and Cash Equivalents (Sep 30, 2006) | $1,181,234 |
| Total Debt (Long-term + Current) | $970,144 |
| Medical Expense Ratio (MER) | 84.3% |
| SG&A Expense Ratio | 14.2% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 46.2% to $15.76 billion for the nine months ended September 30, 2006, compared to $10.76 billion in the prior year period. This was driven primarily by a 148% increase in Medicare premiums due to the launch of stand-alone PDP products and growth in Medicare Advantage members.
- Profitability: Net income rose 41.5% to $332.4 million from $235.0 million in the prior year. The prior year included a one-time tax benefit of $22.8 million and expenses related to a physician class action settlement ($44.8 million after-tax) and Hurricane Katrina ($4.2 million after-tax).
- Membership: Total medical membership grew 58.0% to 11.1 million. Government segment membership surged 103.0% (driven by 3.5 million new PDP members), while Commercial segment membership grew 3.6%.
- Acquisitions: Acquired CHA Health in May 2006 for approximately $65.8 million, adding roughly 88,400 members to the Commercial segment.
- Debt Structure: Issued $500 million of 6.45% senior notes in May 2006 and replaced a $600 million credit facility with a new $1.0 billion facility in July 2006. Repaid $300 million of maturing senior notes in August 2006.
Guidance, Outlook, and Risks
- Outlook: Management expects full-year 2006 Medicare premium revenues to nearly double compared to 2005. The consolidated SG&A expense ratio is expected to improve to a range of 13.5% to 14.5% for the full year. The effective tax rate is projected to be between 35% and 37% for 2006.
- Part D Risk Corridors: The company estimates net amounts owed to CMS under risk corridor provisions of $432.5 million as of September 30, 2006, expected to settle in 2007. This amount is projected to reach $600 million to $800 million by year-end.
- Specific Plan Performance: The "Complete" stand-alone PDP plan (12% of PDP membership) operated at a loss with a 133% MER for the quarter due to benefits exceeding standard reimbursable levels.
- Risks and Contingencies:
- Government Contracts: Significant exposure to Medicare and TRICARE contracts; Puerto Rico Medicaid contracts face uncertainty regarding renewal and terms.
- Regulatory: Subject to ongoing reviews by state and federal authorities regarding claims practices, pricing, and compliance.
- Legal: Various lawsuits pending, including employment litigation, provider disputes, and challenges to Medicare program implementation.
- Capital Requirements: Anticipated capital contributions of $165 million to $215 million in Q4 2006 to meet regulatory capital requirements for state-regulated subsidiaries.
Investor Verification Checklist
- Verify the sustainability of the 148% growth in Medicare premiums and the associated Medical Expense Ratio (MER) trends for new PDP products.
- Confirm the final settlement amount of the $432.5 million CMS risk corridor receivable expected in 2007.
- Monitor the performance of the "Complete" PDP plan, which is currently operating at a significant loss.
- Review the status of Puerto Rico Medicaid contract renewals and potential revenue impacts.
- Assess the impact of the new $1.0 billion credit facility and the company's leverage ratios against covenants.
- Track the resolution of pending legal proceedings and regulatory investigations mentioned in Note 10.